scholarly journals Sa1248 Late Adult-Onset Inflammatory Bowel Disease Patients Require Surgery Earlier During Their Disease Course Compared to Early Adult-Onset Patients

2012 ◽  
Vol 142 (5) ◽  
pp. S-253-S-254 ◽  
Author(s):  
Christina Y. Ha ◽  
Theodore M. Bayless ◽  
Alain Bitton ◽  
Judy H. Cho ◽  
Richard H. Duerr ◽  
...  
2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Sanam Soomro ◽  
Suresh Venkateswaran ◽  
Kamala Vanarsa ◽  
Marwa Kharboutli ◽  
Malavika Nidhi ◽  
...  

AbstractIn the search for improved stool biomarkers for inflammatory bowel disease (IBD), an aptamer-based screen of 1129 stool proteins was conducted using stool samples from an IBD cohort. Here we report that of the 20 proteins subsequently validated by ELISA, stool Ferritin, Fibrinogen, Haptoglobin, Hemoglobin, Lipocalin-2, MMP-12, MMP-9, Myeloperoxidase, PGRP-S, Properdin, Resistin, Serpin A4, and TIMP-1 are significantly elevated in both ulcerative colitis (UC) and Crohn’s disease (CD) compared to controls. When tested in a longitudinal cohort of 50 UC patients at 4 time-points, fecal Fibrinogen, MMP-8, PGRP-S, and TIMP-2 show the strongest positive correlation with concurrent PUCAI and PGA scores and are superior to fecal calprotectin. Unlike fecal calprotectin, baseline stool Fibrinogen, MMP-12, PGRP-S, TIMP-1, and TIMP-2 can predict clinical remission at Week-4. Here we show that stool proteins identified using the comprehensive aptamer-based screen are superior to fecal calprotectin alone in disease monitoring and prediction in IBD.


2021 ◽  
pp. 100979
Author(s):  
Marie Villumsen ◽  
Astrid Blicher Schelde ◽  
Espen Jimenez-Solem ◽  
Tine Jess ◽  
Kristine Højgaard Allin

2018 ◽  
Vol 53 (6) ◽  
pp. 708-713 ◽  
Author(s):  
Anat Yerushalmy-Feler ◽  
Amir Ben-Tov ◽  
Yael Weintraub ◽  
Achiya Amir ◽  
Tut Galai ◽  
...  

2019 ◽  
Vol 156 (6) ◽  
pp. S-831
Author(s):  
Sherman Picardo ◽  
Remo Panaccione ◽  
Gilaad Kaplan ◽  
Cynthia H. Seow ◽  
Jennifer deBruyn ◽  
...  

2019 ◽  
Vol 25 (12) ◽  
pp. 1945-1956 ◽  
Author(s):  
Gertrude van den Brink ◽  
Luuk Stapersma ◽  
Anna Sophia Bom ◽  
Dimitris Rizopolous ◽  
C Janneke van der Woude ◽  
...  

Abstract Background Anxiety and depressive symptoms are prevalent in patients with inflammatory bowel disease (IBD) and may negatively influence disease course. Disease activity could be affected positively by treatment of psychological symptoms. We investigated the effect of cognitive behavioral therapy (CBT) on clinical disease course in 10–25-year-old IBD patients experiencing subclinical anxiety and/or depression. Methods In this multicenter parallel group randomized controlled trial, IBD patients were randomized to disease-specific CBT in addition to standard medical care (CBT + care us usual [CAU]) or CAU only. The primary outcome was time to first relapse in the first 12 months. Secondary outcomes were clinical disease activity, fecal calprotectin, and C-reactive protein (CRP). Survival analyses and linear mixed models were performed to compare groups. Results Seventy patients were randomized (CBT+CAU = 37, CAU = 33), with a mean age of 18.3 years (±50% < 18 y, 31.4% male, 51.4% Crohn’s disease, 93% in remission). Time to first relapse did not differ between patients in the CBT+CAU group vs the CAU group (n = 65, P = 0.915). Furthermore, clinical disease activity, fecal calprotectin, and CRP did not significantly change over time between/within both groups. Exploratory analyses in 10–18-year-old patients showed a 9% increase per month of fecal calprotectin and a 7% increase per month of serum CRP in the CAU group, which was not seen in the CAU+CBT group. Conclusions CBT did not influence time to relapse in young IBD patients with subclinical anxiety and/or depression. However, exploratory analyses may suggest a beneficial effect of CBT on inflammatory markers in children.


2019 ◽  
Vol 13 (Supplement_1) ◽  
pp. S417-S418
Author(s):  
S Picardo ◽  
R Panaccione ◽  
G Kaplan ◽  
C Seow ◽  
J deBruyn ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document